81 FR 66048 - National Institute of Neurological Disorders and Stroke

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health

Federal Register Volume 81, Issue 186 (September 26, 2016)

Page Range		66048-66049
FR Document		2016-23143

Federal Register, Volume 81 Issue 186 (Monday, September 26, 2016)

[Federal Register Volume 81, Number 186 (Monday, September 26, 2016)]
[Notices]
[Pages 66048-66049]
From the Federal Register Online  [www.thefederalregister.org]
[FR Doc No: 2016-23143]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Neurological Disorders and Stroke

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. App.), notice is hereby given of an Interagency Pain 
Research Coordinating Committee (IPRCC) meeting.
    The meeting will feature invited speakers and discussions of 
committee business items including a progress report on implementation 
of the National Pain Strategy, updates on the Federal Pain Research 
Strategy and new pain initiatives.
    The meeting will be open to the public and accessible by live 
webcast and conference call.

    Name of Committee: Interagency Pain Research Coordinating 
Committee.
    Type of meeting: Open Meeting.
    Date: October 31, 2016.
    Time: 8:30 a.m. to 5:00 p.m. *Eastern Time*--Approximate end 
time.
    Agenda: The meeting will feature invited speakers and 
discussions of Committee business items including a progress report 
on implementation of the National Pain Strategy, updates on the 
Federal Pain Research Strategy and new pain initiatives.
    Place: National Institutes of Health, Building 31C, 6th Floor, 
Room 10, 31 Center Drive, Bethesda, MD 20892.
    Cost: The meeting is free and open to the public.
    Webcast Live: http://videocast.nih.gov/.
    Deadlines: Notification of intent to present oral comments: 
Monday, October 17, 2016, by 5:00 p.m. ET.
    Submission of written/electronic statement for oral comments: 
Monday, October 24, 2016, by 5:00 p.m. ET.
    Submission of written comments: Monday, October 24, 2016, by 
5:00 p.m. ET.
    Access: Medical Center Metro (Red Line). Visitor Information: 
http://www.nih.gov/about/visitor/index.htm.
    Contact Person: Linda L. Porter, Ph.D., Pain Policy Advisor, 
Office of Pain Policy, Officer of the Director, National Institute 
of Neurological Disorders and Stroke, NIH, 31 Center Drive, Room 
8A31, Bethesda, MD 20892, Phone: (301) 451-4460, Email: 
[email protected].


[[Page 66049]]


    Please Note:
    Any member of the public interested in presenting oral comments to 
the Committee must notify the Contact Person listed on this notice by 
5:00 p.m. ET on Monday, October 17, 2016, with their request to present 
oral comments at the meeting. Interested individuals and 
representatives of organizations must submit a written/electronic copy 
of the oral statement/comments including a brief description of the 
organization represented by 5:00 p.m. ET on Thursday, October 24, 2016.
    Statements submitted will become a part of the public record. Only 
one representative of an organization will be allowed to present oral 
comments on behalf of that organization, and presentations will be 
limited to three to five minutes per speaker, depending on number of 
speakers to be accommodated within the allotted time. Speakers will be 
assigned a time to speak in the order of the date and time when their 
request to speak is received, along with the required submission of the 
written/electronic statement by the specified deadline. If special 
accommodations are needed, please email the Contact Person listed 
above.
    In addition, any interested person may submit written comments to 
the IPRCC prior to the meeting by sending the comments to the Contact 
Person listed on this notice by 5:00 p.m. ET, Monday, October 24, 2016. 
The comments should include the name and, when applicable, the business 
or professional affiliation of the interested person. All written 
comments received by the deadlines for both oral and written public 
comments will be provided to the IPRCC for their consideration and will 
become part of the public record.
    The meeting will be open to the public and webcast live on the 
Internet. If you experience any technical problems with the webcast, 
please call the NIH IT Service Desk at (301) 496-4357, toll free (866) 
319-4357, for webcast issues.
    Individuals who participate in person or by using the wed service 
and who need special assistance, such as captioning, should submit a 
request to the Contact Person listed on this notice at least seven days 
prior to the meeting.
    As a part of security procedures, attendees should be prepared to 
present a photo ID during the security process to get on the NIH 
campus. For a full description, please see: http://www.nih.gov/about/visitorsecurity.htm.
    Information about the IPRCC is available on the Web site: http://iprcc.nih.gov/.

    Dated: September 20, 2016.
Sylvia L. Neal,
Program Analyst, Office of Federal Advisory Committee Policy.
[FR Doc. 2016-23143 Filed 9-23-16; 8:45 am]
BILLING CODE 4140-01-P

66048 Federal Register / Vol. 81, No. 186 / Monday, September 26, 2016 / Notices

requirements of 35 U.S.C. 209 and 37 No. 61/771,251 filed March 1, 2013, inspection and, to the extent permitted
CFR part 404. entitled ‘‘Methods of Producing by law, will not be released under the
Complete applications for a license in Enriched Populations of Tumor Reactive Freedom of Information Act, 5 U.S.C.
the prospective field of use that are filed T Cells from Peripheral Blood’’ [HHS 552.
in response to this notice will be treated Reference No. E–085–2013/0–US–01]; Dated: September 20, 2016.
as objections to the grant of the and PCT Application No. PCT/US2013/
Richard U. Rodriguez,
contemplated Exclusive 038813 filed April 30, 2013 entitled
Commercialization Patent License Associate Director, Technology Transfer
‘‘Methods of Producing Enriched
Center, National Cancer Institute.
Agreement. Comments and objections Populations of Tumor Reactive T Cells
submitted to this notice will not be [FR Doc. 2016–23048 Filed 9–23–16; 8:45 am]
from Peripheral Blood’’ [HHS Reference
made available for public inspection No. E–085–2013/0–PCT–02] (and U.S. BILLING CODE 4140–01–P

and, to the extent permitted by law, will and foreign patent applications claiming
not be released under the Freedom of priority to the aforementioned
Information Act, 5 U.S.C. 552. applications). DEPARTMENT OF HEALTH AND
The patent rights in these inventions HUMAN SERVICES
Dated: September 21, 2016.
Richard U. Rodriguez, have been assigned to the government of
National Institutes of Health
the United States of America.
Associate Director, Technology Transfer
Center, National Cancer Institute.
The prospective Start-up Exclusive National Institute of Neurological
Evaluation Patent License territory may Disorders and Stroke
[FR Doc. 2016–23134 Filed 9–23–16; 8:45 am]
be worldwide and the field of use may
BILLING CODE 4140–01–P Pursuant to section 10(a) of the
be limited to the development,
manufacture and commercialization of Federal Advisory Committee Act, as
autologous tumor-reactive peripheral amended (5 U.S.C. App.), notice is
DEPARTMENT OF HEALTH AND hereby given of an Interagency Pain
blood T cell therapy products as set
HUMAN SERVICES Research Coordinating Committee
forth in the Licensed Patent Rights for
National Institutes of Health the treatment of metastatic follicular (IPRCC) meeting.
thyroid cancer and metastatic soft tissue The meeting will feature invited
Prospective Grant of Start-Up sarcomas in humans. speakers and discussions of committee
Exclusive Evaluation Patent License: The present invention describes a business items including a progress
Development of Autologous Tumor- method of selecting highly tumor- report on implementation of the
reactive T Cells Isolated From reactive T cells from autologous National Pain Strategy, updates on the
Peripheral Blood for the Treatment of peripheral blood samples based on the Federal Pain Research Strategy and new
Metastatic Follicular Thyroid Cancer expression of two specific T cell surface pain initiatives.
and Metastatic Soft Tissue Sarcomas markers: Programmed cell death protein The meeting will be open to the
1 (PD–1; CD279) and/or T cell Ig- and public and accessible by live webcast
AGENCY: National Institutes of Health. mucin-domain-containing molecule-3 and conference call.
ACTION: Notice. (TIM–3). Following selection, isolated Name of Committee: Interagency Pain
cells may be expanded and reinfused Research Coordinating Committee.
SUMMARY: The National Cancer Institute,
into the donor patient as part of an Type of meeting: Open Meeting.
National Institutes of Health,
adoptive cell transfer therapeutic Date: October 31, 2016.
Department of Health and Human Time: 8:30 a.m. to 5:00 p.m. *Eastern
regimen. The disclosed method may be
Services, is contemplating the grant of a Time*—Approximate end time.
advantageous over existing approaches
Start-up Exclusive Evaluation Patent Agenda: The meeting will feature invited
which rely on the isolation of T cells
License to MedGene Therapeutics, Inc. speakers and discussions of Committee
from tumor samples since it eliminates
(‘‘MedGene’’) located in Bethesda, MD business items including a progress report on
the cost and complications associated
to practice the inventions embodied in implementation of the National Pain
with tumor resection, as well as Strategy, updates on the Federal Pain
the patent applications listed
provides a T cell product for patients Research Strategy and new pain initiatives.
Supplementary Information section of
without resectable lesions. Place: National Institutes of Health,
this notice. This notice is made in accordance Building 31C, 6th Floor, Room 10, 31 Center
DATES: Only written comments and/or with 35 U.S.C. 209 and 37 CFR part 404. Drive, Bethesda, MD 20892.
applications for a license which are The prospective Start-up Exclusive Cost: The meeting is free and open to the
received by the NCI Technology Evaluation Patent License will be public.
Transfer Center on or before October 11, royalty bearing and the may be granted Webcast Live: http://videocast.nih.gov/.
2016 will be considered. unless within fifteen (15) days from the Deadlines: Notification of intent to present
ADDRESSES: Requests for copies of the oral comments: Monday, October 17, 2016,
date of this published notice, the by 5:00 p.m. ET.
patent applications, inquiries, and National Cancer Institute receives Submission of written/electronic statement
comments relating to the contemplated written evidence and argument that for oral comments: Monday, October 24,
Start-up Exclusive Evaluation Patent establishes that the grant of the license 2016, by 5:00 p.m. ET.
License should be directed to: Andrew would not be consistent with the Submission of written comments: Monday,
Burke, Ph.D., Licensing and Patenting requirements of 35 U.S.C. 209 and 37 October 24, 2016, by 5:00 p.m. ET.
Manager, NCI Technology Transfer CFR part 404. Access: Medical Center Metro (Red Line).
Center, 9609 Medical Center Drive, RM Complete applications for a license in Visitor Information: http://www.nih.gov/
mstockstill on DSK3G9T082PROD with NOTICES

1E530 MSC 9702, Bethesda, MD 20892– the prospective field of use that are about/visitor/index.htm.
9702 (for business mail), Rockville, MD timely filed in response to this notice Contact Person: Linda L. Porter, Ph.D.,
20850–9702 Telephone: (240) 276–5530; Pain Policy Advisor, Office of Pain Policy,
will be treated as objections to the grant Officer of the Director, National Institute of
Facsimile: (240) 276–5504; Email: of the contemplated Start-up Exclusive Neurological Disorders and Stroke, NIH, 31
andy.burke@nih.gov. Evaluation Patent License. Comments Center Drive, Room 8A31, Bethesda, MD
SUPPLEMENTARY INFORMATION: United and objections submitted to this notice 20892, Phone: (301) 451–4460, Email:
States Provisional Patent Application will not be made available for public Linda.Porter@nih.gov.

VerDate Sep<11>2014 19:40 Sep 23, 2016 Jkt 238001 PO 00000 Frm 00054 Fmt 4703 Sfmt 4703 E:\FR\FM\26SEN1.SGM 26SEN1

Document Created: 2018-02-09 13:23:00
Document Modified: 2018-02-09 13:23:00

Category		Regulatory Information
Collection		Federal Register
sudoc Class		AE 2.7: GS 4.107: AE 2.106:
Publisher		Office of the Federal Register, National Archives and Records Administration
Section		Notices
Dates		October 31, 2016.
FR Citation		81 FR 66048

81 FR 66048 - National Institute of Neurological Disorders and Stroke

DEPARTMENT OF HEALTH AND HUMAN SERVICESNational Institutes of Health

Federal Register Volume 81, Issue 186 (September 26, 2016)

DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health